
via Georgia State University
Treatment of SARS-CoV-2 infection with a new antiviral drug, MK-4482/EIDD-2801 or Molnupiravir, completely suppresses virus transmission within 24 hours, researchers in the Institute for Biomedical Sciences at Georgia State University have discovered.
The group led by Dr. Richard Plemper, Distinguished University Professor at Georgia State, originally discovered that the drug is potent against influenza viruses.
“This is the first demonstration of an orally available drug to rapidly block SARS-CoV-2 transmission,” said Plemper. “MK-4482/EIDD-2801 could be game-changing.”
Interrupting widespread community transmission of SARS-CoV-2 until mass vaccination is available is paramount to managing COVID-19 and mitigating the catastrophic consequences of the pandemic.
Because the drug can be taken by mouth, treatment can be started early for a potentially three-fold benefit: inhibit patients’ progress to severe disease, shorten the infectious phase to ease the emotional and socioeconomic toll of prolonged patient isolation and rapidly silence local outbreaks.
“We noted early on that MK-4482/EIDD-2801 has broad-spectrum activity against respiratory RNA viruses and that treating infected animals by mouth with the drug lowers the amount of shed viral particles by several orders of magnitude, dramatically reducing transmission,” said Plemper. “These properties made MK-4482/EIDD/2801 a powerful candidate for pharmacologic control of COVID-19.”
In the study published in Nature Microbiology, Plemper’s team repurposed MK-4482/EIDD-2801 against SARS-CoV-2 and used a ferret model to test the effect of the drug on halting virus spread.
“We believe ferrets are a relevant transmission model because they readily spread SARS-CoV-2, but mostly do not develop severe disease, which closely resembles SARS-CoV-2 spread in young adults,” said Dr. Robert Cox, a postdoctoral fellow in the Plemper group and a co-lead author of the study.
The researchers infected ferrets with SARS-CoV-2 and initiated treatment with MK-4482/EIDD-2801 when the animals started to shed virus from the nose.
“When we co-housed those infected and then treated source animals with untreated contact ferrets in the same cage, none of the contacts became infected,” said Josef Wolf, a doctoral student in the Plemper lab and co-lead author of the study. By comparison, all contacts of source ferrets that had received placebo became infected.
If these ferret-based data translate to humans, COVID-19 patients treated with the drug could become non-infectious within 24 hours after the beginning of treatment.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Molnupiravir
- The latest COVID-19 news and case numbers from around the states and territories
Here's a quick wrap of the COVID-19 news and case numbers from each Australian jurisdiction from the past week.
- Oral Antivirals for High-risk COVID-19 Patients
US Pharmacist. 2022;47(7):34-41. A consideration for molnupiravir is its theoretical risk for contributing to mutant variants of SARS-CoV-2. As such, molnupiravir use should be avoided in patients ...
- Paxlovid gets closer to full approval
Welcome to The Hill’s Health Care newsletter{beacon} Health Care Health Care The Big Story Paxlovid gets closer to full approval A panel of independent experts voted this ...
- F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment
While an agency analysis did find signs of Covid “rebound,” the drug significantly reduces hospitalizations and deaths, researchers said.
- Merck asks EMA to reconsider recommendation to reject authorizing COVID pill molnupiravir
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser. Is this happening to you frequently? Please report it on our ...
Go deeper with Google Headlines on:
Molnupiravir
[google_news title=”” keyword=”Molnupiravir” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
SARS-CoV-2 transmission
- Study: A nasal spray protects against coronavirus infection, including recent immune-evasive variants
Researchers have developed a molecule that is, when administered nasally, extremely effective in preventing the disease caused by all known variants of the SARS-CoV-2 virus. The molecule can be a key ...
- Crucial data about the origins of COVID is only now being disclosed. A scientist weighs the impact of the delay
I was the Australian representative on the international World Health Organization (WHO) investigation into the origins of SARS-CoV-2. I went to Wuhan on a fact-finding mission in early 2021. I ...
- What is a raccoon dog and did it really cause the COVID pandemic? Here's what scientists say
A cute, dog-like animal has emerged as the chief culprit for the first transmission of the COVID virus to humans, thanks to newly revealed genetic evidence from the Huanan Seafood Wholesale Market in ...
- Research highlights the potential risk of secondary SARS-CoV-2 transmission from wild rats
Please use one of the following formats to cite this article in your essay, paper or report: APA Sai Lomte, Tarun. (2023, March 16). Research highlights the potential risk of secondary SARS-CoV-2 ...
- What does the science say about the origin of the SARS-CoV-2 pandemic?
Two U.S. intelligence agencies reportedly support the lab leak theory — with low-to-moderate confidence. No evidence has been shared. Scientists have strong evidence of animal spillover at a market.
Go deeper with Google Headlines on:
SARS-CoV-2 transmission
[google_news title=”” keyword=”SARS-CoV-2 transmission” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]